Literature DB >> 26047207

Clostridium difficile Infection Among Veterans Health Administration Patients.

Yinong Young-Xu1, Jennifer L Kuntz2, Dale N Gerding3, Julia Neily1, Peter Mills1, Erik R Dubberke4, Margaret A Olsen4, Ciarán P Kelly5, Cédric Mahé6.   

Abstract

OBJECTIVE: To report on the prevalence and incidence of Clostridium difficile infection (CDI) from 2009 to 2013 among Veterans Healthcare Administration patients
DESIGN: A retrospective descriptive analysis of data extracted from a large electronic medical record (EMR) database
SETTING: Data were acquired from VHA healthcare records from 2009 to 2013 that included outpatient clinical visits, long-term care, and hospitalized care as well as pharmacy and laboratory information.
RESULTS: In 2009, there were 10,207 CDI episodes, and in 2013, there were 12,143 CDI episodes, an increase of 19.0%. The overall CDI rate increased by 8.4% from 193 episodes per 100,000 patient years in 2009 to 209 episodes per 100,000 patient years in 2013. Of the CDI episodes identified in 2009, 58% were identified during a hospitalization, and 42% were identified in an outpatient setting. In 2013, 44% of the CDI episodes were identified in an outpatient setting.
CONCLUSION: This is one of the largest studies that has utilized timely EMR data to describe the current CDI epidemiology at the VHA. Despite an aging population with greater burden of comorbidity than the general US population, our data show that VHA CDI rates stabilized between 2011 and 2013 following increases likely attributable to the introduction of the more sensitive nucleic acid amplification tests (NAATs). The findings in this report will help establish an accurate benchmark against which both current and future VA CDI prevention initiatives can be measured.

Entities:  

Mesh:

Year:  2015        PMID: 26047207     DOI: 10.1017/ice.2015.138

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  6 in total

1.  Incidence and economic burden of Clostridioides difficile infection in Ontario: a retrospective population-based study.

Authors:  Jennifer A Pereira; Allison McGeer; Antigona Tomovici; Alex Selmani; Ayman Chit
Journal:  CMAJ Open       Date:  2020-01-30

2.  The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases.

Authors:  Margaret A Olsen; Yinong Young-Xu; Dustin Stwalley; Ciarán P Kelly; Dale N Gerding; Mohammed J Saeed; Cedric Mahé; Erik R Dubberke
Journal:  BMC Infect Dis       Date:  2016-04-22       Impact factor: 3.090

3.  Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis.

Authors:  Alexandre R Marra; Eli N Perencevich; Richard E Nelson; Matthew Samore; Karim Khader; Hsiu-Yin Chiang; Margaret L Chorazy; Loreen A Herwaldt; Daniel J Diekema; Michelle F Kuxhausen; Amy Blevins; Melissa A Ward; Jennifer S McDanel; Rajeshwari Nair; Erin Balkenende; Marin L Schweizer
Journal:  JAMA Netw Open       Date:  2020-01-03

4.  National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014.

Authors:  Kelly R Reveles; Kenneth A Lawson; Eric M Mortensen; Mary Jo V Pugh; Jim M Koeller; Jacqueline R Argamany; Christopher R Frei
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

5.  A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States.

Authors:  Daniel J Livorsi; Margaret L Chorazy; Marin L Schweizer; Erin C Balkenende; Amy E Blevins; Rajeshwari Nair; Matthew H Samore; Richard E Nelson; Karim Khader; Eli N Perencevich
Journal:  Antimicrob Resist Infect Control       Date:  2018-04-24       Impact factor: 4.887

6.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis.

Authors:  Evelyn Balsells; Ting Shi; Callum Leese; Iona Lyell; John Burrows; Camilla Wiuff; Harry Campbell; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.